Phase 4 N=32 Effect of Injectable Platelet-Rich Fibrin (i-PRF) in Initial Treatment of Chronic Periodontitis
Periodontitis
Primary: Periodontal Pocket Depth-PPD — 3.735; 3.696 mm — p=0.429
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=82 DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence
Urinary Incontinence
Primary: Number of Subjects With Treatment-Emergent Adverse Events — 20; 10 Participants — p=0.963
Phase 3 N=51 Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy
Diabetic Peripheral Neuropathy
Primary: Pain Scores From Composite Visual Analog Scale — 6.5; 1.2; 4.5; 0.5 units on a scale
N/A N=43 Performance of Toric Hydrogel Lenses Following A Refit With Toric Silicone Hydrogel Lenses for 1 Month
Ametropia
Primary: Number of Participants With Lens Centration Assessment by the Investigator - Methafilcon A Toric Contact Lenses — 40; 3; 0 Participants
N/A N=9 Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants
Bloodstream Infections · Short Bowel Syndrome · Development
Primary: Number of Participants With Bloodstream Infections (BSI) — 0; 1 Participants
N/A N=74 Moderate vs Deep Neuromuscular Block on Biotrauma During Laparoscopy
Pneumoperitoneum
Primary: Change of Cytokine — 35.9; 12.2; 31.4; 22.9 pg/ml
N/A N=298 A Multi-Reader Multi-Case Pivotal Trial
Breast Cancer
Primary: Correct Lesion Localization: Area Under the Receiver Operating Characteristic (ROC) Curve (AUC) for FFDM + DBT Versus FFDM Alone Based on Probability of Malignancy (POM)…
N/A N=12 Evaluation of the Safety and Performance of the HARMONI® Toric Lens
Aphakia · Corneal Astigmatism · Cataract
Primary: Mean Manifest Refraction Cylinder (MRCYL) for Eyes Implanted With HMTIOL — -0.50; -0.57 diopter
Phase 2 N=83 A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction
Acute Myocardial Infarction · Moderate Renal Impairment
Primary: Percent of Participants With at Least One Occurrence of Treatment-emergent Renal Serious Adverse Events (SAEs) (SAF) — 1.9; 14.3 percentage of participants
N/A N=211 Dietary Flavanols and Dentate Gyrus Function
Memory Loss
Primary: Modified Benton Recognition Task (ModBent) — 2807.98; 2579.94; 2603.65; 2732.79 ms — p=.393
Phase 2 N=24 Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Time in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage) — 0.98; 0.89; 0.69…
Phase 3 N=81 Anxiety and Recurrent Abdominal Pain in Children
Abdominal Pain · Anxiety
Primary: Clinical Global Impression Scale - Improvement (CGI-I) Will be Used to Assess Overall Global Illness Improvement. CGI-I Scores of 1 (Very Much Improved) or 2 (Much…
Phase 2 N=300 Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events
Reperfusion Injury · STEMI
Primary: Area Under the Curve (AUC) of Serum Creatine Kinase Isoenzyme Type Muscle-brain (CK-MB) — 6582.0; 6738.3; 5252.2; 5471.9 ng*hr/mL
Phase 3 N=40 Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study
Non-Small-Cell Lung Carcinoma
Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging — 16.5; 7.1 Months — p=0.12511
Phase 1 N=24 Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A
Malaria
Primary: Safety of MMV390048 - Number of Adverse Events — 13; 0; 9; 12 Number of adverse events